Literature DB >> 26333304

Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro.

Nuobei Zhang1, Xin Chen2.   

Abstract

O-GlcNAcylation is a monosaccharide modification by a residue of N-acetylglucosamine (GlcNAc) attached to serine or threonine moieties on nuclear and cytoplasmic proteins. O-GlcNAcylation is dynamically regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Increasing evidence suggests that O-GlcNAcylation is involved in a variety of human cancers. However, the exact role of O-GlcNAcylation in tumor progression remains unclear. Here, we show that O-GlcNAcylation accelerates oncogenic phenotypes of gastric cancer. First, cell models with increased or decreased O-GlcNAcylation were constructed by OGT overexpression, downregulation of OGA activity with specific inhibitor Thiamet-G, or silence of OGT. MTT assays indicated that O-GlcNAcylation increased proliferation of gastric cancer cells. Soft agar assay and Transwell assays showed that O-GlcNAcylation significantly enhanced cellular colony formation, migration, and invasion in vitro. Akt1 activity was stimulated by upregulation of phosphorylation at Ser473 mediated by elevated O-GlcNAcylation. The enhanced cell invasion by Thiamet-G treatment was suppressed by PI3K inhibitor LY294002. Although the cell invasion induced by Thiamet-G was reduced by Akt1 shRNA, it was still higher in comparison with that to the control (cells with Akt1 shRNA alone). And Akt1 overexpression promoted Thiamet-G-induced cell invasion. These results suggested that O-GlcNAcylation enhanced oncogenic phenotypes possibly partially involving PI3K/Akt signaling pathway.
© 2015 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  O-GlcNAcylation; PI3K/Akt; gastric cancer; invasion; migration; proliferation

Mesh:

Substances:

Year:  2015        PMID: 26333304     DOI: 10.1002/bab.1441

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  11 in total

Review 1.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

2.  MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1.

Authors:  Yu Mao; Liang Li; Jia Liu; Le Wang; Yan Zhou
Journal:  Oncotarget       Date:  2016-08-09

3.  GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer.

Authors:  Shimeng Cheng; Qiqi Mao; Yabing Dong; Jie Ren; Lina Su; Jianlan Liu; Qingmei Liu; Jing Zhou; Xiaolu Ye; Shudan Zheng; Ningwen Zhu
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

4.  Effects of Acute Cold Stress on Liver O-GlcNAcylation and Glycometabolism in Mice.

Authors:  Ruizhi Yao; Yuying Yang; Shuai Lian; Hongzhao Shi; Peng Liu; Yang Liu; Huanmin Yang; Shize Li
Journal:  Int J Mol Sci       Date:  2018-09-18       Impact factor: 5.923

5.  Increased O-GlcNAcylation promotes IGF-1 receptor/PhosphatidyI Inositol-3 kinase/Akt pathway in cervical cancer cells.

Authors:  Victoria Jiménez-Castillo; Daniela Illescas-Barbosa; Edgar Zenteno; Beatriz Xóchitl Ávila-Curiel; Maria Cristina Castañeda-Patlán; Martha Robles-Flores; Daniel Montante-Montes De Oca; Eduardo Pérez-Campos; Anayetzin Torres-Rivera; Abdelouhab Bouaboud; Patrick Pagesy; Carlos Josué Solórzano-Mata; Tarik Issad
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

6.  Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking.

Authors:  Kai Niu; Qifang Li; Yuan Liu; Yi Qiao; Bingbing Li; Chao Wei; Kunrui Wang; Lu'an Cui; Canlei Zheng; Rong Wang; Li Zhang; Honghua Zhang; Bing Sun; Bin Yu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-04       Impact factor: 2.629

7.  Silencing the Nucleocytoplasmic O-GlcNAc Transferase Reduces Proliferation, Adhesion, and Migration of Cancer and Fetal Human Colon Cell Lines.

Authors:  Agata Steenackers; Stéphanie Olivier-Van Stichelen; Steffi F Baldini; Vanessa Dehennaut; Robert-Alain Toillon; Xuefen Le Bourhis; Ikram El Yazidi-Belkoura; Tony Lefebvre
Journal:  Front Endocrinol (Lausanne)       Date:  2016-05-25       Impact factor: 5.555

Review 8.  O-GlcNAcylation and the Metabolic Shift in High-Proliferating Cells: All the Evidence Suggests that Sugars Dictate the Flux of Lipid Biogenesis in Tumor Processes.

Authors:  Steffi F Baldini; Tony Lefebvre
Journal:  Front Oncol       Date:  2016-01-22       Impact factor: 6.244

9.  Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling.

Authors:  Mingzuo Jiang; Zhaoyan Qiu; Song Zhang; Xing Fan; Xiqiang Cai; Bing Xu; Xiaowei Li; Jinfeng Zhou; Xiangyuan Zhang; Yi Chu; Weijie Wang; Jie Liang; Tamas Horvath; Xiaoyong Yang; Kaichun Wu; Yongzhan Nie; Daiming Fan
Journal:  Oncotarget       Date:  2016-09-20

Review 10.  Cross-Dysregulation of O-GlcNAcylation and PI3K/AKT/mTOR Axis in Human Chronic Diseases.

Authors:  Ninon Very; Anne-Sophie Vercoutter-Edouart; Tony Lefebvre; Stéphan Hardivillé; Ikram El Yazidi-Belkoura
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-09       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.